Polaris International Holdings Inc. announce its medical division, ProCannas, has begun development of a unique and proprietary transdermal patch capable of delivering cannabinoids directly through the skin. This hallmark solution is intended to address a significant, unmet need for individuals requiring long-term, time released delivery. The company believes, subject to testing and trials to be initiated by participating physicians, that the patch may able to deliver cannabinoids for up to 48 hours.

The Company further expects that this mechanism of delivery could revolutionize the way cannabinoids are introduced into the blood stream minimizing the negative effects on lungs and other organs commonly seen in other delivery methods. The Company expects to be ready to begin trials in 90 days. The company intends to target a broad range of specialties with this novel product, including but not limited to sports medicine, pain management, neurology, and osteopathic medicine.